SEC Form 8-K Summary
Registrant: Deep Medicine Acquisition Corp. The request identifies Trugolf Holdings, Inc., but the filing text names Deep Medicine Acquisition Corp. as the registrant and relates to its proposed business combination with Chijet Inc.
Reporting date: September 16, 2022; the filing was signed September 20, 2022. This is a transaction update rather than a periodic financial report.
Business Context and Transaction Update
Deep Medicine Acquisition Corp. entered into a Business Combination Agreement on July 12, 2022, with Chijet Inc., its shareholders, Chijet Motor Company, Inc. as the proposed public holding company, and Chijet Motor (USA) Company, Inc. as merger subsidiary.
Under the proposed transaction, Deep Medicine and Chijet would become wholly owned subsidiaries of Chijet Motor Company, Inc. The parties entered into Amendment No. 2 on September 16, 2022, extending the due diligence period and valuation review deadline from September 20, 2022, to September 30, 2022. All other terms of the Business Combination Agreement remain in effect.
Financial Metrics and Liquidity
The filing does not provide current-period or prior-period revenue, profit, cash flow, margins, debt, liquidity, valuation, or other operating financial metrics. It is focused on an amendment to the proposed business combination.
Material Changes Versus Prior Disclosures
- Amendment No. 2 extends the diligence expiration date to September 30, 2022.
- The diligence process includes reviewing Chijet and its operations and completing Deep Medicine’s revised valuation determination.
- The Business Combination Agreement otherwise remains in full force and effect.
- A Form F-4 registration statement and related proxy statement/prospectus had not yet been filed with or declared effective by the SEC as of the filing.
Outlook, Risks, and Contingencies
Completion of the transaction remains subject to due diligence, valuation, stockholder approval, regulatory and listing requirements, applicable closing conditions, and other contractual conditions. The transaction may not be completed or may be terminated.
- Completion may be delayed or may not occur before Deep Medicine’s business combination deadline.
- Excessive shareholder redemptions or failure to satisfy Nasdaq initial listing standards could prevent closing.
- Chijet’s ability to recognize revenue, secure contracts, execute growth plans, and develop effective internal controls is uncertain.
- Chijet faces risks from competition, vehicle and electric-vehicle market conditions, technology changes, regulation, economic conditions, COVID-19 effects, and its early-stage business.
- The parties may not realize the anticipated benefits or projected financial effects of the transaction, and the filing notes a lack of useful financial information for accurately estimating future revenue and capital expenditures.
- Legal proceedings, governmental actions, operating disruptions, or failure to satisfy closing conditions could adversely affect the transaction.
The filing contains forward-looking statements and cautions investors not to place undue reliance on them. The registration statement, proxy statement/prospectus, and other future SEC filings are expected to provide additional transaction and risk information.
Key Facts for Investors to Verify
- Confirm the correct issuer and transaction counterparties, because the filing names Deep Medicine Acquisition Corp. and Chijet rather than Trugolf Holdings, Inc.
- Review Amendment No. 2 and confirm the September 30, 2022 diligence and revised valuation deadline.
- Verify whether the Form F-4 registration statement was subsequently filed and declared effective.
- Review the final transaction valuation, ownership structure, redemption assumptions, financing, and closing conditions when disclosed.
- Assess Chijet’s historical financial statements, revenue recognition, liquidity, debt, capital requirements, internal controls, and operating risks.
- Confirm whether the Business Combination was completed, extended, or terminated and whether Nasdaq listing requirements were satisfied.